Biofrontera AG Stock
€0.34
Your prediction
Biofrontera AG Stock
Pros and Cons of Biofrontera AG in the next few years
Pros
Cons
Performance of Biofrontera AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biofrontera AG | -16.850% | 1.807% | -4.520% | -70.862% | -16.953% | -86.091% | -94.894% |
| Formycon AG | -0.810% | -0.574% | -5.972% | -39.945% | -22.401% | -29.822% | 26.979% |
| MagForce AG | - | 40.000% | 16.667% | 250.000% | 337.500% | -99.912% | -99.925% |
| Medigene AG | 1.010% | -5.145% | -31.395% | -11.940% | -7.233% | -62.516% | -83.095% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.After looking at the financial statements provided for Biofrontera, a company operating in the Biotechnology & Medical Research industry, it's evident that the company has experienced several ups and downs in recent times. The overall financial health of the firm raises questions and deserves to be analyzed in more depth. In the following paragraphs, we will examine the key aspects of Biofrontera's financials, outlining both the pros and cons.
Growth in revenue: The company has demonstrated an increase in total revenues on a YoY basis. Between 2020 and 2021, the total revenue grew from €30.35m to €28.79m, a positive signal for investors.
Decrease in cost of revenue: Looking at the statements, the cost of revenue has dropped. This suggests that Biofrontera's gross profit margin may have improved, pointing to the company's ability to generate more revenue with lower costs.
Comments
